Structure Therapeutics (GPCR) vs Ocular Therapeutix (OCUL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Structure Therapeutics (GPCR) has outperformed Ocular Therapeutix (OCUL) over the past year, losing 53.0% versus a loss of 54.5%. Ocular Therapeutix is the larger company by market cap ($1.23 billion vs $1.15 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GPCR | OCUL |
|---|---|---|
| Share price | $16.13 | $5.57 |
| Market cap | $1.15B | $1.23B |
| 1-day change | -5.78% | -4.95% |
| YTD return | -76.81% | -54.12% |
| 1-year return | -53.00% | -54.49% |
| 5-year return | — | -14.83% |
| EPS (TTM) | $-3.90 | $-1.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $51.95M |
| Revenue growth (YoY) | — | -18.47% |
| Net income (latest FY) | $-141.20M | $-265.94M |
| Gross margin | — | 87.35% |
| Operating margin | — | -519.75% |
| Net margin | — | -511.90% |
| 52-week high | $94.90 | $16.44 |
| 52-week low | $16.06 | $5.54 |
| Distance from 52-week high | -83.00% | -66.12% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +550.09% | +361.94% |
| Average volume | 1.18M | 3.03M |
| Shares outstanding | 71.59M | 220.02M |
| Employees | 281 | 325 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Structure Therapeutics
GPCR stock →Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions.
Health Care · Biotechnology: Pharmaceutical Preparations · 281 employees
About Ocular Therapeutix
OCUL stock →Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 325 employees
GPCR vs OCUL FAQ
Which is bigger, Structure Therapeutics or Ocular Therapeutix?
Ocular Therapeutix (OCUL) is larger, with a market capitalization of $1.23B compared with $1.15B for Structure Therapeutics (GPCR).
Which stock has performed better over the past year, GPCR or OCUL?
GPCR returned -53.00% over the past 12 months, compared with -54.49% for OCUL (price return, excluding dividends). Past performance does not predict future results.
Are Structure Therapeutics and Ocular Therapeutix in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.